41.76
-0.39(-0.93%)
Currency In USD
| Previous Close | 42.15 |
| Open | 41.78 |
| Day High | 42.43 |
| Day Low | 40.31 |
| 52-Week High | 56.05 |
| 52-Week Low | 18.53 |
| Volume | 876,361 |
| Average Volume | 1.36M |
| Market Cap | 2.93B |
| PE | -10.16 |
| EPS | -4.11 |
| Moving Average 50 Days | 46.9 |
| Moving Average 200 Days | 30.39 |
| Change | -0.39 |
If you invested $1000 in Vera Therapeutics, Inc. (VERA) since IPO date, it would be worth $3,631.3 as of February 21, 2026 at a share price of $41.76. Whereas If you bought $1000 worth of Vera Therapeutics, Inc. (VERA) shares 3 years ago, it would be worth $5,194.03 as of February 21, 2026 at a share price of $41.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
GlobeNewswire Inc.
Jan 28, 2026 12:30 PM GMT
BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological dise
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2026 12:30 PM GMT
BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
GlobeNewswire Inc.
Jan 07, 2026 12:30 PM GMT
FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN. BRISBANE, Calif